{"DataElement":{"publicId":"2688951","version":"1","preferredName":"Breast Carcinoma Transplantation Time Status Type","preferredDefinition":"Information related to the status of breast cancer at the time of transplant.","longName":"BRST_CRCN_TRN_ST_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2688946","version":"1","preferredName":"Breast Carcinoma Transplantation Time Status","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._The grafting of tissues from one individual to another or place to place within a single individual._The continuum of experience in which events pass from the future through the present to the past._A condition or state at a particular time.","longName":"BRST_CRCN_TRN_ST","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2475941","version":"1","preferredName":"Breast Carcinoma","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002","longName":"C4872","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11C95199-159B-5C1E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-19","modifiedBy":"ONEDATA","dateModified":"2006-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2674595","version":"1","preferredName":"Transplantation Time Status","preferredDefinition":"The grafting of tissues from one individual to another or place to place within a single individual.:the continuum of experience in which events pass from the future through the present to the past.:A condition or state at a particular time.","longName":"C15342:C25207:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"384B648C-219F-1050-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-22","modifiedBy":"ONEDATA","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4BADC5-0742-737E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".Updated def for \"breast carcinoma\". No version needed. AK 9/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2688948","version":"1","preferredName":"Breast Carcinoma Status Type","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._A condition or state at a particular time._Something distinguishable as an identifiable class based on common qualities.","longName":"BRST_CRCN_ST_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"29","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Relapse","valueDescription":"RECURRENT DISEASE","ValueMeaning":{"publicId":"2568039","version":"1","preferredName":"RECURRENT DISEASE","longName":"2568039","preferredDefinition":"Recurrent disease","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D6D4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-12","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-12","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3C4BE624-D336-0D2B-E044-0003BA3F9857","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ALEYR","dateModified":"2007-10-12","deletedIndicator":"No"},{"value":"1st partial response (PR1)","valueDescription":"Partial Response, Preliminary","ValueMeaning":{"publicId":"2688949","version":"1","preferredName":"Partial Response, Preliminary","longName":"2688949","preferredDefinition":"Preceding all others in time or space or degree.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4BE624-D345-0D2B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeDescription":"User curated long name to support DCI, Modified RANO, ghd, 04.24.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3C4BE624-D35E-0D2B-E044-0003BA3F9857","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ALEYR","dateModified":"2007-10-12","deletedIndicator":"No"},{"value":"Complete Remission (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"2577915","version":"1","preferredName":"Complete Remission","longName":"2577915","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3C4BE624-D36A-0D2B-E044-0003BA3F9857","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ALEYR","dateModified":"2007-10-12","deletedIndicator":"No"},{"value":"Primary refractory","valueDescription":"Primary Refractory","ValueMeaning":{"publicId":"2578379","version":"1","preferredName":"Primary Refractory","longName":"2578379","preferredDefinition":"Primary disease, resistant to treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF38-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-22","modifiedBy":"REEVESD","dateModified":"2006-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3C4BE624-D37F-0D2B-E044-0003BA3F9857","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ALEYR","dateModified":"2007-10-12","deletedIndicator":"No"},{"value":"Never treated","valueDescription":"Never Therapeutic Procedure","ValueMeaning":{"publicId":"2685077","version":"1","preferredName":"Never Therapeutic Procedure","longName":"2685077","preferredDefinition":"Not ever; at no time in the past (or future).: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Never","conceptCode":"C70543","definition":"Not ever; at no time in the past (or future).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B83BB14-A509-653C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-02","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3C4BE624-D38B-0D2B-E044-0003BA3F9857","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ALEYR","dateModified":"2007-10-12","deletedIndicator":"No"},{"value":"Adjuvant (Stage II, III only)","valueDescription":"Adjuvant Therapy","ValueMeaning":{"publicId":"2567165","version":"1","preferredName":"Adjuvant Therapy","longName":"2567165","preferredDefinition":"Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant Therapy","conceptCode":"C15675","definition":"Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-11-05","modifiedBy":"COOPERM","dateModified":"2017-04-11","changeDescription":"Updated definition to match current NCIt. mc 4/11/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3C4BE624-D3A0-0D2B-E044-0003BA3F9857","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ALEYR","dateModified":"2007-10-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2688947","version":"1","preferredName":"Breast Carcinoma Status Type","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C4872:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4BE61D-3562-09E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ONEDATA","dateModified":"2007-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4BE61D-3573-09E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"HARTLEYG","dateModified":"2018-04-24","changeDescription":". Updated def for \"breast carcinoma\". No version needed. AK 9/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_brst_ca_stat_hsct","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the status of the br","type":"Preferred Question Text","description":"What was the status of the breast cancer at the time of transplantation?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2688951","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis.value = \"breast cancer\" AND PerformedDiagnosis > PerformedObservation.dateRange IS LESS THAN OR EQUAL TO PerformedSubstanceAdministration.dateRange AND PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Administer Hematopoietic Cell Product {Transplantation}\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4BE61D-3589-09E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"KUMMEROA","dateModified":"2021-04-30","changeDescription":".Updated def for \"breast carcinoma\". No version needed. AK 9/18/12 System generated def displayed as alt def. 2021-4-30 ak","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}